Board of Directors

Erika Kjellberg Eriksson has held board assignments and senior positions in pharmaceutical, biotech and medtech companies for more than 25 years. She has extensive experience from working in both listed and unlisted companies and vast board experience.

Born: 1962
Education: BSc in Economics, Uppsala University (1985).
Other current assignments: Erika Kjellberg Eriksson is CEO of Nexttobe AB, chairman of the board of directors of Linum AB, Brixton Medical AB, Aros Biotech, Lumina Adhesives AB, AllgoHolding AB, Lokon Pharma AB, and Tanea Medical AB, Director of Vivolux AB and Findolon AB.

Holdings in the Company: Erika Kjellberg Eriksson owns 199,000 shares in the Company.

She is independent in relation to the company and its management, but not in relation to major shareholders.

Finn Sander Albrechtsen has more than 16 years of international leadership experience from the life science and diagnostics industry. This includes seven years with Dako and Agilent Technologies in positions focused on product development, from portfolio- and project management to leading the global R&D function. Between 2015 and 2021, Finn was VP of R&D and Business Development for the Microbiology division within Thermo Fisher Scientific.

Born: 1967
Education: BSc in Electrical Engineering, Technical University of Denmark.
Other ongoing assignments: Finn Sander Albrechtsen is Head of Global R&D at SSI Diagnostica Group and a member of the board of directors of Panacea Diagnostics Ltd.

Holdings in the Company: Finn Sander Albrechtsen owns 100,000 shares in the company.

He is independent in relation to the company and its management and in relation to major shareholders.

Hans Johansson has extensive experience and a broad contact network from his previous roles in the life sciences and diagnostics industry, most recently as vice president, head of Companion Diagnostics at Thermo Fisher’s Speciality Diagnostics Group. His previous positions include vice president global marketing and business development at Thermo Fisher’s Immuno Diagnostics Division, CEO of Pyrosequencing/Personal Chemistry (now Biotage), and head of laboratories at Pharmacia Biotechnology AB.

Born: 1954
Education: MSc in chemical engineering
Other ongoing assignments: Hans Johansson is chairman of the board of directors of Myrtila AB and Doloradix AB, a member of the board of directors of Immunovia AB (publ), and Swelife.

Holdings in the Company: Hans Johansson owns 23,528 shares in the Company.

He is independent in relation to the company and its management and in relation to major shareholders.

Karin Fischer has more than 15 years of global commercial experience from both strategic and operative positions. She has also been stationed in the US. Karin has worked for companies such as Johnson & Johnson, Getinge, Xvivo Perfusion and RLS Global. She was CEO for more than four years at RLS Global, listed at Nasdaq First North.

Born: 1976
Education: BSc in Business administration and Economics, University of Aberdeen.
Other ongoing assignments: Karin Fischer is currently CEO at Biolin Scientific AB, a company within the AddLife group.

Holdings in the Company: Karin Fischer does not own any shares in the Company.

She is independent in relation to the company and its management and in relation to major shareholders.

Mats Nilsson is a professor of molecular diagnostics, has founded several companies in the biotech industry and is one of the founders of Q-linea. He has extensive board experience and has served on the board of Elos MedTech AB, which is listed on Nasdaq Stockholm.

Born: 1969
Education: Associate professor of molecular medicine, Uppsala University (2003); PhD in medical genetics, Uppsala University (1998); MSc in biology, Uppsala University (1998).
Other ongoing assignments: Mats Nilsson is Scientific Director and professor of biochemistry at the Science for Life Laboratory at Stockholm University. He also serves as member of the board of directors of EMPE Diagnostics AB, Countagen AB, Aplex Bio AB and Biocyclica Holding AB.

Holdings in the Company: Mats Nilsson owns 444,000 shares in the Company. He owns an additional 586,654 shares in the Company through the related company Biocyclia Holding AB.

He is independent in relation to major shareholders, but not in relation to the company and its management.

Nina Korfu-Pedersen is currently Chief Transformation Officer for control & staff functions at SEB where she also has had roles as SEB’s CFO and global manager for Business Support & Operations. She has long experience of leading major change initiatives globally, operationally and strategically in different industries and roles, both in the consulting industry and in line manager roles. She has more than 15 years of experience in international leadership roles.

Born: 1973
Education: Nina holds a master exam from Handelshöyskolen BI (Norway) and a Master of Arts in International Relations from University of Reading (UK).
Other ongoing assignments: Nina Korfu-Pedersen is a member of the Financial Reporting Board.

Holdings in the Company: Nina Korfu-Pedersen does not own any shares in the Company.

She is independent in relation to the company and its management and in relation to major shareholders